Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A
Authors
Keywords
RAS, Leukemogenesis, Drug target, Plasma membrane translocation, Signal transduction
Journal
Journal of Hematology & Oncology
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-12-30
DOI
10.1186/s13045-015-0226-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KRAS as a Therapeutic Target
- (2015) F. McCormick CLINICAL CANCER RESEARCH
- Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
- (2015) A. D. Cox et al. CLINICAL CANCER RESEARCH
- Mechanisms of Membrane Binding of Small GTPase K-Ras4B Farnesylated Hypervariable Region
- (2015) Hyunbum Jang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif
- (2015) Frederick D. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Strategies for modern biomarker and drug development in oncology
- (2014) Alan D Smith et al. Journal of Hematology & Oncology
- MicroRNA-mediated regulation of KRAS in cancer
- (2014) Minlee Kim et al. Journal of Hematology & Oncology
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
- (2014) Anna A. Marusiak et al. Nature Communications
- A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets
- (2013) Sophia Adamia et al. CLINICAL CANCER RESEARCH
- Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
- (2013) Sophia Adamia et al. CURRENT CANCER DRUG TARGETS
- Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- MEK and the inhibitors: from bench to bedside
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- B-Raf and the inhibitors: from bench to bedside
- (2013) Tiangui Huang et al. Journal of Hematology & Oncology
- Palmitoylation of oncogenic NRAS is essential for leukemogenesis
- (2010) B. Cuiffo et al. BLOOD
- Raf-independent, PP2A-dependent MEK activation in response to ERK silencing
- (2009) Dongsoon Bae et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Palmitoylation and localisation of RAS isoforms are modulated by the hypervariable linker domain
- (2008) Alex J. Laude et al. JOURNAL OF CELL SCIENCE
- Kras regulatory elements and exon 4A determine mutation specificity in lung cancer
- (2008) Minh D To et al. NATURE GENETICS
- Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis
- (2007) Charles E. Patek et al. EXPERIMENTAL CELL RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now